BioVaxys Technology (TSE:BIOV) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
BioVaxys Technology Corp. has successfully closed the first tranche of its non-brokered private placement, raising $350,000 through the issuance of 7 million units and settling $733,600 of debt with the issuance of over 14 million shares. The funds are earmarked for general working capital to advance the company’s plans, particularly in the field of oncology and infectious diseases, following its acquisition of immunological assets from IMV Inc.
For further insights into TSE:BIOV stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
- Intel Stock (NASDAQ:INTC) Slips Despite Growing Interest in AI
- “…Tied to the Effort From the Administration” Boeing Stock (NYSE:BA) Blasts Up as Boeing Counts on New Top Sales Rep in China: President Trump
- “We Do Not Have Conflicting Interests….” Microsoft Stock (NASDAQ:MSFT) Gains on New Plan to be the Agentic AI Internet’s Backbone

